

Fig. 1a




Fig. 1b




Fig. 1c

4/25




Fig. 1d

5/25




Fig. 1e

6/25




Fig. 1f

7/25





Fig. 1g

Fig. 2a



9/25




Fig. 2b

10/25



Fig. 3




Fig. 4a

12/25




Fig. 4b






Fig. 4c

14/25




Atorvastatin




Lovastatin

Fig. 5a

15/25




Pravastatin Sodium




Fluvastatin

Fig. 5b

16/25



Mevastatin



Simvastatin

Fig. 5c

10056609 04233

2025-09-08 10:12:30

Ragi cells

IFN- γ /Simva
L-Mevalonate

IFN- γ /Simva

IFN- γ /Atorva

IFN- γ /Lova

IFN- γ /Prava

IFN- γ

Control




Fig. 6




Fig. 7




Fig. 8





Fig. 9a

Statin treatment

-

+



CD40L staining

Fig. 9b

10056608-042302





Fig. 9c

23/25

Day 10 after Tx



Day 14 after Tx





Fig. 10

Day 6 after onset of arthritis



Day 12 after onset of arthritis




Fig. 11

	³ H] Thymidine incorporation [cpm]	IFN- γ production [pg/ml]
Control	13,830 (\pm 7,078)	60,112 (\pm 13,532)
Low dose	6,508 (\pm 6,499) *	36,368 (\pm 8,005) *
High dose	5,221 (\pm 7,632) *	29,805 (\pm 8,114) *

Fig. 12